Login
$NTRA
$293.25 After hours

$NTRA SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 Form 4: Sheena Jonathan, Director

Sold 1,500 shares ($479K)

10 Nov 2026 Form 4: Sheena Jonathan, Director

Sold 3,086 shares ($976K) · Sold 64 shares ($19.8K)

12 Nov 2026 FORM S-8
12 Nov 2026 S-3ASR
06 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

AUSTIN, Texas, November 5, 2026 /BUSINESS WIRE/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2026.

05 Nov 2026 SCHEDULE 13G
04 Nov 2026 Form 4: Sheena Jonathan, Director

Sold 112 shares ($44.8K)

04 Nov 2026 Form 4: Rabinowitz Matthew, Director

Sold 748 shares ($299K)

04 Nov 2026 Form 4: Rabinowitz Daniel, SEC. AND CHIEF LEGAL OFFICER

Sold 341 shares ($136K)

04 Nov 2026 Form 4: Moshkevich Solomon, PRESIDENT, CLINICALDIAGNOSTICS

Sold 3,419 shares ($1.4M)

04 Nov 2026 Form 4: Fesko John, PRESIDENT, CHIEF BUS. OFFICER

Sold 302 shares ($121K)

04 Nov 2026 Form 4: Chapman Steven Leonard, Director

Sold 3,801 shares ($1.57M)

04 Nov 2026 Form 4: Brophy Michael Burkes, CHIEF FINANCIAL OFFICER

Sold 325 shares ($130K) · Sold 470 shares ($184K)

03 Nov 2026 144
02 Nov 2026 144
02 Nov 2026 144
02 Nov 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support